Patents by Inventor Gabriela Rossi
Gabriela Rossi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9512158Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: December 17, 2012Date of Patent: December 6, 2016Assignee: NEWLINK GENETICS CORPORATIONInventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
-
Patent number: 9474771Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: August 28, 2013Date of Patent: October 25, 2016Assignee: CENTRAL IOWA HEALTH SYSTEMInventors: Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
-
Patent number: 9474801Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: August 14, 2013Date of Patent: October 25, 2016Assignee: CENTRAL IOWA HEALTH SYSTEMInventors: Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
-
Publication number: 20160089397Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through a combination of ex vivo gene therapy protocols and cell enchment, tumor cells are engineered to express an ? (1,3)galactosyl epitope and optionally the tumor associated antigens mesothelin and carcinoembryonic antigen. After administration of the compositions of the invention to patients, the production of increased antibody titers to certain cell-surface markers, including mesothelin, calreticulin, and carcinembryonic antigen (CEA) positively correlates with an increased overall survival.Type: ApplicationFiled: May 15, 2014Publication date: March 31, 2016Inventors: Gabriela ROSSI, Charles LINK
-
Patent number: 9090643Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: December 17, 2012Date of Patent: July 28, 2015Assignee: NEWLINK GENETICS CORPORATIONInventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
-
Patent number: 8916169Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: December 17, 2012Date of Patent: December 23, 2014Assignee: NewLink Genetics CorporationInventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
-
Publication number: 20140072597Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: August 28, 2013Publication date: March 13, 2014Applicant: Central Iowa Health SystemInventors: Charles J. LINK, JR., Tatiana Seregina, Gabriela Rossi
-
Publication number: 20140037692Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: August 14, 2013Publication date: February 6, 2014Applicant: CENTRAL IOWA HEALTH SYSTEMInventors: Charles J. LINK, JR., Tatiana Seregina, Gabriela Rossi
-
Patent number: 8551474Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: September 24, 2010Date of Patent: October 8, 2013Assignee: Central Iowa Health SystemInventors: Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
-
Patent number: 8535658Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ? (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: September 9, 2010Date of Patent: September 17, 2013Assignee: Central Iowa Health SystemInventors: Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
-
Patent number: 8357777Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epi topes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: June 30, 2011Date of Patent: January 22, 2013Assignee: Newlink GeneticsInventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
-
Publication number: 20120003251Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epi topes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicant: NewLink GeneticsInventors: Mario R. MAUTINO, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
-
Publication number: 20110250233Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ? (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: September 9, 2010Publication date: October 13, 2011Inventors: Charles J. Link, JR., Tatiana Seregina, Gabriela Rossi
-
Patent number: 7998486Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: October 24, 2007Date of Patent: August 16, 2011Assignee: NewLink Genetics CorporationInventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
-
Publication number: 20110086067Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: September 24, 2010Publication date: April 14, 2011Applicant: Central Iowa Health SystemInventors: Charles J. LINK, JR., Tatiana Seregina, Gabriela Rossi
-
Patent number: 7763461Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ? (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: GrantFiled: September 19, 2006Date of Patent: July 27, 2010Assignee: Iowa Health SystemInventors: Charles J. Link, Jr., Tatiana Seregina, Gabriela Rossi
-
Publication number: 20090060930Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce ?Gal epitopes or ?Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-?Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: October 24, 2007Publication date: March 5, 2009Inventors: Mario R. Mautino, Nicholas N. Vahanian, Won-Bin Young, Gabriela Rossi, Charles J. Link, Firoz Jaipuri
-
Publication number: 20070014774Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ? (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: September 19, 2006Publication date: January 18, 2007Inventors: CHARLES LINK, TATIANA SEREGINA, GABRIELA ROSSI
-
Publication number: 20070014775Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ? galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: September 19, 2006Publication date: January 18, 2007Inventors: CHARLES LINK, TATIANA SEREGINA, GABRIELA ROSSI
-
Publication number: 20050201993Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an ?(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The ?-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.Type: ApplicationFiled: December 16, 2004Publication date: September 15, 2005Inventors: Charles Link, Tatiana Seregina, Gabriela Rossi